VETOQUINOL SA |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 94.6 EUR | -1.05% |
|
-5.02% | -7.62% |
| Apr. 30 | Vetoquinol: down after sales update | CF |
| Apr. 29 | Vetoquinol SA Reports Sales Results for the First Quarter of Fiscal 2024 | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Vetoquinol SA specializes in the research, development, production and marketing of veterinary drugs and products for pets (67.7% of net sales; dogs, cats, etc.) and livestock (32.3%; cattle, pigs, poultry, etc.). The group's activity is organized around 4 product families:
- antibiotics;
- anti-inflammatories;
- cardiology and nephrology treatments;
- other: anti-parasitics, vaccines, and nutritional products.
At the end of 2022, the group had 5 production sites throughout the world.
Net sales are distributed geographically as follows: Europe (46.7%), the Americas (36%) and Asia/Pacific (17.3%).
Sector
Pharmaceuticals
Calendar
2024-05-27
- Annual General Meeting
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
HOLD
Number of Analysts
6
Last Close Price
94.6
EUR
Average target price
105.7
EUR
Spread / Average Target
+11.70%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -7.62% | 1.21B | |
| -9.19% | 6.67B | |
| +24.75% | 3.7B | |
| -1.11% | 3.21B | |
| +6.08% | 1.52B | |
| -15.13% | 1.37B | |
| -25.63% | 1.24B | |
| -10.84% | 1.17B | |
| -.--% | 1.05B | |
| -7.07% | 832M |
- Stock Market
- Equities
- VETO Stock
- News Vetoquinol SA
- Vetoquinol Chairman to Step Down; CEO Named Successor
